Literature DB >> 18809833

Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis.

M Tanaka1, T Matsushita, T Tateishi, H Ochi, Y Kawano, F-J Mei, M Minohara, H Murai, J-I Kira.   

Abstract

BACKGROUND: We reported the emergence of a distinct myelitis in patients with atopic diathesis (atopic myelitis [AM]) by a nationwide survey throughout Japan. Similar cases have recently been reported in Caucasians. Pathologic studies of biopsied spinal cord specimens revealed chronic active inflammation with eosinophilic infiltration.
OBJECTIVE: To clarify the cytokine/chemokine alterations in CSF from patients with AM in comparison to other causes of myelitis.
METHODS: We measured 27 cytokines, chemokines, and growth factors simultaneously in CSF from 22 patients with AM, 20 with opticospinal multiple sclerosis (OSMS), 11 with HTLV-1-associated myelopathy (HAM), 9 with Sjögren syndrome-related myelitis (SM), and 20 with other noninflammatory neurologic diseases (OND), using a fluorescent bead-based immunoassay.
RESULTS: In patients with AM, CCL11 and interleukin (IL)-9 were significantly increased as compared with patients with OND and other myelitis while in patients with OSMS interferon-gamma and granulocyte-colony stimulating factor levels were significantly higher than in patients with OND and other causes of myelitis. Significant increase of IL-17 in comparison to patients with OND was found only in patients with OSMS, irrespective of presence or absence of anti-aquaporin-4 (AQP4) antibody. In patients with HAM, CXCL10 and CCL5 were higher than in patients with OND and other myelitis. In patients with SM, CCL3 and CCL4 were higher than in patients with OND. In patients with AM, CCL11, IL-9, and IL-1 receptor antagonist (IL-1ra) showed positive correlations with the final Kurtzke Expanded Disability Status Scale scores while IL-1ra and IL-12(p70) had positive correlations with disease duration.
CONCLUSION: Intrathecal upregulation of CCL11 and Th2 cytokines is characteristic of atopic myelitis, which is distinct from interleukin-17/interferon-gamma-related autoimmune condition of opticospinal multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18809833     DOI: 10.1212/01.wnl.0000326589.57128.c3

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  21 in total

Review 1.  Interleukin-9 as a T helper type 17 cytokine.

Authors:  Elizabeth C Nowak; Randolph J Noelle
Journal:  Immunology       Date:  2010-10       Impact factor: 7.397

2.  Interleukin 9 alterations linked to alzheimer disease in african americans.

Authors:  Whitney Wharton; Alexander L Kollhoff; Umesh Gangishetti; Danielle D Verble; Samsara Upadhya; Henrik Zetterberg; Veena Kumar; Kelly D Watts; Andrea J Kippels; Marla Gearing; J Christina Howell; Monica W Parker; William T Hu
Journal:  Ann Neurol       Date:  2019-07-22       Impact factor: 10.422

3.  Clinical relevance of serum aquaporin-4 antibody levels in neuromyelitis optica.

Authors:  Noriko Isobe; Tomomi Yonekawa; Takuya Matsushita; Katsuhisa Masaki; Satoshi Yoshimura; Jakub Fichna; Shu Chen; Jadwiga Furmaniak; Bernard Rees Smith; Jun-Ichi Kira
Journal:  Neurochem Res       Date:  2013-03-02       Impact factor: 3.996

4.  Immunodominant T cell determinants of aquaporin-4, the autoantigen associated with neuromyelitis optica.

Authors:  Patricia A Nelson; Mojgan Khodadoust; Thomas Prodhomme; Collin Spencer; Juan Carlos Patarroyo; Michel Varrin-Doyer; Joseph D Ho; Robert M Stroud; Scott S Zamvil
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

5.  CSF CXCL10, CXCL9, and neopterin as candidate prognostic biomarkers for HTLV-1-associated myelopathy/tropical spastic paraparesis.

Authors:  Tomoo Sato; Ariella Coler-Reilly; Atae Utsunomiya; Natsumi Araya; Naoko Yagishita; Hitoshi Ando; Junji Yamauchi; Eisuke Inoue; Takahiko Ueno; Yasuhiro Hasegawa; Kusuki Nishioka; Toshihiro Nakajima; Steven Jacobson; Shuji Izumo; Yoshihisa Yamano
Journal:  PLoS Negl Trop Dis       Date:  2013-10-10

6.  Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis.

Authors:  Takuya Matsushita; Takahisa Tateishi; Noriko Isobe; Tomomi Yonekawa; Ryo Yamasaki; Dai Matsuse; Hiroyuki Murai; Jun-Ichi Kira
Journal:  PLoS One       Date:  2013-04-18       Impact factor: 3.240

Review 7.  Molecular pathogenesis of neuromyelitis optica.

Authors:  Wajih Bukhari; Michael H Barnett; Kerri Prain; Simon A Broadley
Journal:  Int J Mol Sci       Date:  2012-10-11       Impact factor: 5.923

8.  Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.

Authors:  Zi-Ye Song; Ryo Yamasaki; Yuji Kawano; Shinya Sato; Katsuhisa Masaki; Satoshi Yoshimura; Dai Matsuse; Hiroyuki Murai; Takuya Matsushita; Jun-ichi Kira
Journal:  PLoS One       Date:  2015-04-28       Impact factor: 3.240

9.  Therapeutic benefits of an oral vitamin B1 derivative for human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

Authors:  Jun-Ichi Kira
Journal:  BMC Med       Date:  2013-08-15       Impact factor: 8.775

Review 10.  Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications.

Authors:  Giordani Rodrigues Dos Passos; Douglas Kazutoshi Sato; Jefferson Becker; Kazuo Fujihara
Journal:  Mediators Inflamm       Date:  2016-01-28       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.